| Patent application number | Description | Published |
|---|
| 20080274133 | Soluble Bifunctional Proteins - The present invention provides a soluble bifunctional protein comprising an association between a T cell receptor and a superantigen. Also provided are therapeutic compositions comprising said bifunctional proteins and methods for the use thereof. | 11-06-2008 |
| 20090208447 | Polypeptides - The present invention provides polypeptides having the property of binding to a given Class I pMHC CHARACTERISED IN THAT said polypeptide has a K | 08-20-2009 |
| 20090214551 | High Affinity Hiv T Cell Receptors - The present invention provides TCRs having an affinity (K | 08-27-2009 |
| 20100047220 | Substances - This invention provides a cell presenting at least one T cell receptor (TCR) anchored to the membrane by a transmembrane sequence, said TCR comprising an interchain disulfide bond between extracellular constant domain residues which is not present in native TCRs. | 02-25-2010 |
| 20100068186 | High affinity telomerase t cell receptors - The present invention provides T cell receptors (TCRs) having the property of binding to ILAKFLHWL-HLA-A*0201 and comprising at least one TCR α chain variable domain and/or at least one TCR β chain variable domain CHARACTERISED IN THAT said TCR has a K | 03-18-2010 |
| 20100113300 | T CELL RECEPTOR DISPLAY - A proteinaceous particle, for example a bacteriophage, ribosome or cell, displaying on its surface a T-cell receptor (TCR). The displayed TCR is preferably a heterodimer having a non-native disulfide bond between constant domain residues. Such display particles may be used for the creation of diverse TCR libraries for the identification of high affinity TCRs. Several high affinities are disclosed. | 05-06-2010 |
| 20100135997 | POLYPEPTIDE MONOMERS AND DIMERS CONTAINING MUTATED ILT - The present invention provides monomeric and dimeric polypeptide fusions comprising mutated human ILT molecules and immunoglobulin Fc segments. Such compostions are useful, either alone or associated with a therapeutic agent, for targeting cells expressing Class I pMHC molecules. | 06-03-2010 |
| 20110014169 | HIGH AFFINITY NY-ESO T CELL RECEPTORS - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 01-20-2011 |
| 20110038842 | High affinity ny-eso t cell receptor - The present invention provides T cell receptors (TCRs) having the property of binding to SLLMWITQC-HLA-A*0201, the SLLMWITQC peptide being derived from the NY-ESO-1 protein which is expressed by a range of tumour cells. The TCRs have a K | 02-17-2011 |
